Clinical characteristics and treatment outcomes among the hospitalized elderly patients with COVID-19 during the late pandemic phase in central Taiwan
Background: There is a lack of information regarding outcomes of elderly patients hospitalized with COVID-19 following the widespread use of COVID-19 vaccines and antiviral agents. Methods: A retrospective study was conducted between January and August 2022, enrolling patients aged 65 years or older. Patients were categorized into two groups: ‘old’ (65–79 years) and ‘oldest-old’ (80 years or more). Multivariate regression was employed to identify independent prognostic factors for in-hospital mortality. Results: A total of 797 patients were enrolled, including 428 old and 369 oldest-old patients. In each subgroup, 66.6 % and 59.6 % of patients received at least one dose of the COVID-19 vaccine, respectively. Approximately 40 % of the patients received oral antiviral agents either before or upon hospital admission. A greater percentage of the oldest-old patients received remdesivir (53.4 % versus 39.7 %, p < 0.001), dexamethasone (49.3 % versus 36.7 %, p < 0.001), and tocilizumab (10.0 % versus 6.8 %, p < 0.001) than old patients. The mortality rate was comparable between the two age subgroups (14 % versus 15.2 %). Independent predictors of in-hospital mortality included disease severity and comorbidities such as end-stage renal disease (ESRD), cirrhosis, solid tumours, and haematologic malignancies. Ageing was not correlated with increased in-hospital mortality across all comorbidity subgroups. Conclusions: In the later stages of the pandemic, with widespread vaccination and advancements in COVID-19 treatments, outcomes for hospitalized elderly and oldest-old patients with COVID-19 have improved. The influence of age on in-hospital mortality has diminished, while comorbidities such as ESRD, cirrhosis, solid tumours, and hematologic malignancies have been associated with mortality..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Journal of Microbiology, Immunology and Infection - 57(2024), 2, Seite 257-268 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chieh-Lung Chen [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Aged |
|---|
| doi: |
10.1016/j.jmii.2024.01.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ095782214 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ095782214 | ||
| 003 | DE-627 | ||
| 005 | 20240413122409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jmii.2024.01.006 |2 doi | |
| 035 | |a (DE-627)DOAJ095782214 | ||
| 035 | |a (DE-599)DOAJ8197b2d399594e2eb1bb71757d9dbf82 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Chieh-Lung Chen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical characteristics and treatment outcomes among the hospitalized elderly patients with COVID-19 during the late pandemic phase in central Taiwan |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: There is a lack of information regarding outcomes of elderly patients hospitalized with COVID-19 following the widespread use of COVID-19 vaccines and antiviral agents. Methods: A retrospective study was conducted between January and August 2022, enrolling patients aged 65 years or older. Patients were categorized into two groups: ‘old’ (65–79 years) and ‘oldest-old’ (80 years or more). Multivariate regression was employed to identify independent prognostic factors for in-hospital mortality. Results: A total of 797 patients were enrolled, including 428 old and 369 oldest-old patients. In each subgroup, 66.6 % and 59.6 % of patients received at least one dose of the COVID-19 vaccine, respectively. Approximately 40 % of the patients received oral antiviral agents either before or upon hospital admission. A greater percentage of the oldest-old patients received remdesivir (53.4 % versus 39.7 %, p < 0.001), dexamethasone (49.3 % versus 36.7 %, p < 0.001), and tocilizumab (10.0 % versus 6.8 %, p < 0.001) than old patients. The mortality rate was comparable between the two age subgroups (14 % versus 15.2 %). Independent predictors of in-hospital mortality included disease severity and comorbidities such as end-stage renal disease (ESRD), cirrhosis, solid tumours, and haematologic malignancies. Ageing was not correlated with increased in-hospital mortality across all comorbidity subgroups. Conclusions: In the later stages of the pandemic, with widespread vaccination and advancements in COVID-19 treatments, outcomes for hospitalized elderly and oldest-old patients with COVID-19 have improved. The influence of age on in-hospital mortality has diminished, while comorbidities such as ESRD, cirrhosis, solid tumours, and hematologic malignancies have been associated with mortality. | ||
| 650 | 4 | |a Aged | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hospitalization | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Oldest-old | |
| 650 | 4 | |a Prognosis | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Chi-Kang Teng |e verfasserin |4 aut | |
| 700 | 0 | |a Wei-Cheng Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Shinn-Jye Liang |e verfasserin |4 aut | |
| 700 | 0 | |a Chih-Yen Tu |e verfasserin |4 aut | |
| 700 | 0 | |a Hong-Mo Shih |e verfasserin |4 aut | |
| 700 | 0 | |a Wan-Ju Cheng |e verfasserin |4 aut | |
| 700 | 0 | |a Yu-Chao Lin |e verfasserin |4 aut | |
| 700 | 0 | |a Po-Ren Hsueh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Microbiology, Immunology and Infection |d Elsevier, 2017 |g 57(2024), 2, Seite 257-268 |w (DE-627)DOAJ000087645 |x 16841182 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2024 |g number:2 |g pages:257-268 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jmii.2024.01.006 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/8197b2d399594e2eb1bb71757d9dbf82 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1684118224000070 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1684-1182 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2024 |e 2 |h 257-268 | ||